Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the company’s post-pandemic transformation. The year reflected a deliberate shift away from episodic COVID-19 demand toward sustained, science-driven growth engines across vaccines, cardiometabolic disease, oncology, and rare diseases, reinforcing Pfizer’s long-term strategic repositioning.
“2025 was not about replacing pandemic-era revenues, but about rebuilding Pfizer around durable scientific platforms,” said Dr. Albert Bourla, Chairman and Chief Executive Officer of Pfizer. “Our performance reflects a company transitioning from episodic demand to sustained therapeutic-area leadership.”
Transition from COVID-19 to Core Franchise Growth
While COVID-19 vaccine and antiviral revenues continued their expected normalization in 2025, Pfizer delivered operational growth across its non-COVID core portfolio. This shift improved revenue quality and reduced volatility, signaling a structurally more balanced business model anchored in chronic, specialty, and preventive care.
Vaccines: From Emergency Response to Lifecycle Leadership
Vaccines remained a foundational pillar of Pfizer’s portfolio. The Prevnar pneumococcal franchise sustained strong global demand, particularly in adult and high-risk populations, supported by lifecycle management strategies and expanded real-world utilization. ABRYSVO, Pfizer’s RSV vaccine, emerged as a strategically important growth driver, with expanding adoption in older adults and maternal immunization, positioning RSV as a recurring, long-term vaccine market rather than a seasonal opportunity. The COVID-19 vaccine portfolio transitioned fully into a mature, managed franchise, enabling reinvestment into next-generation vaccine platforms.
Cardiometabolic and Rare Disease: Durable, High-Value Franchises
In cardiometabolic disease, ELIQUIS continued to deliver stable, high-quality revenue, reinforcing Pfizer’s strength in chronic cardiovascular care through deep guideline integration and long treatment durations. Pfizer’s rare disease strategy gained further traction through continued growth of VYNDAQEL and VYNDAMAX in transthyretin amyloid cardiomyopathy, supported by improved diagnosis rates, global access expansion, and durable clinical differentiation.
Oncology: Scaling a Future Growth Engine
Oncology showed tangible progress as a long-term growth pillar in 2025. PADCEV delivered strong momentum, driven by expanded indications and increased use in earlier lines of treatment, validating Pfizer’s strategic focus on antibody-drug conjugates and precision oncology. The broader oncology pipeline continues to emphasize targeted therapies, combination regimens, and biomarker-driven development.
R&D Strategy: Focus, Conviction, and Long-Term Value
Across research and development, Pfizer emphasized focus over breadth, prioritizing high-conviction investments in next-generation respiratory vaccines, oncology platforms with combination potential, cardiometabolic and obesity science, and rare diseases with high unmet medical need and long lifecycle durability. This approach reflects a shift toward capital-efficient innovation and sustainable franchise building.
Strategic Outlook
Entering 2026, Pfizer’s strategy is increasingly defined by clarity and discipline, centered on lifecycle-driven vaccine leadership, durable specialty franchises, and the scaling of differentiated oncology assets.
“Pfizer is emerging from this transition more focused, more disciplined, and more science-driven,” Bourla concluded. “Our objective is to build franchises that matter for decades and deliver sustained impact for patients worldwide.”
By